Drugs / TRIN2755
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01259518 | Nov 2009 → Sep 2011 | neoplasm | Trin Therapeutics GmbH | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TriN 2755 | “This is an open-label, parallel-group, two-center, safety, activity and pharmacokinetic study of TriN 2755 given at increasing dose levels as intravenous infusions administered...” NCT01259518 ↗ |
| Modality | Small molecule | “The novel triazene TriN 2755 differs from other triazenes through its physicochemical properties such as high hydrophilicity and photostability” NCT01259518 ↗ |
| Route | Intravenous | “given at increasing dose levels as intravenous infusions administered over 4 hours” NCT01259518 ↗ |